Japanese CRO EPS To Develop And Market Drugs In China
This article was originally published in PharmAsia News
Executive SummaryJapanese CRO EPS has entered the drug development business in China. The company has signed an agreement with Japanese mid-sized drug companies to market two drugs in China. Chinese clinical trials will be starting this year and the company aims for approvals by March 2010. EPS also plans to license five more drugs to market in China, and invest ¥100-¥200 million to start the clinical trials. EPS entered China in 1999, and the company has since established a Beijing EPS subsidiary to support new drug development. (Click here for more - Japanese language
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.